Premium
METOPROLOL—CONTROLLED RELEASE, ZERO ORDER KINETICS
Author(s) -
Kendall M. J.
Publication year - 1989
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1989.tb00235.x
Subject(s) - metoprolol , tolerability , pharmacology , medicine , angina , drug , adverse effect , myocardial infarction
Summary Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used β 1 ‐selective, β‐adrenoceptor blocking drug, (β 1 ,‐blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. It should, therefore, provide an effective well‐tolerated treatment for hypertension and angina pectoris and for use in secondary prevention following a myocardial infarct. The purpose of this review is to consider the need for such a formulation, to describe its pharmaceutical development, review its pharmacology and assess its efficacy and tolerability compared with other available agents.